Oxytrol, Flomax Switches Show Gap Between U.S., U.K. Pathways
This article was originally published in The Tan Sheet
Executive Summary
EU centralized switch has proven difficult, with only two drugs making the transition from Rx to OTC in the European Medicines Agency process, and EU member state switches also remain complex. Boehringer’s Flomax U.K. switch and Merck’s Oxytrol for Women in the U.S. underscore differences in the regulatory paths.
You may also be interested in...
Merck’s Oxytrol Could Be OTC Trailblazer For Chronic Conditions
Merck’s Oxytrol for Women has the opportunity to “create the market” for OTC overactive bladder drugs, as well as encourage other switches for chronic, progressive conditions, marketing consultant Joe McGovern says. The transdermal patch product is slated to launch in September.
GSK Urges Regulatory Changes To Pull EU Market From Doldrums
The time appears right for Rx-to-OTC switches as European Union members struggle to control expanding health budgets in the face of aging populations and the continuing global economic crisis.
Boehringer Launches Switched Flomax Relief MR For BPH In U.K.
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says